Back grey_arrow_rt.gif
 
 
FDA approves Roche's skin cancer drug Erivedge
 
 
  World News | Januar

y 31 2012

Roche and partner Curis are celebrating after getting the green light for Erivedge, their treatment for basal cell carcinoma, the most common type of skin cancer.

Erivedge (vismodegib), a once-a-day pill, is the first treatment for BCC to be approved by the US Food and Drug Administration. The approval comes after a priority (six-month) review and is based on results from a Phase II study that showed Erivedge shrank lesions in 27 of 63 patients with locally advanced BCC and 10 out of 33 patients with metastatic BCC.

The approval comes six weeks ahead of the original action date (March 8) for the drug, which selectively inhibits abnormal signalling in the Hedgehog pathway, "which is implicated in more than 90% of BCC cases," Roche notes. Chief medical officer Hal Barron noted that until now people with advanced BCC "had no approved medicines to help shrink disfiguring or potentially life-threatening lesions".

He added that "we are pleased that in the last six months we have been able to provide two new medicines for different types of advanced skin cancer to people who previously had few or no treatment options", referring to the melanoma drug Zelboraf (vemurafenib), approved by the FDA in August.

The approval, which also comes with a boxed warning of the potential risk of death or severe birth defects to unborn babies, triggers a $10 million payment to Curis. Erivedge will cost $7,500 per month and the duration of treatment per patient is expected be around 10 months.

Simos Simeonidis and Yatin Suneja, analysts at Cowen & Co, issued a research note saying they expect 2015 sales, including Europe where they predict a launch in 2013, of $401 million, with peak 2022 sales of $533 million, resulting in royalties to Curis of $32 million and $43 million, respectively.

-----------------------------

Media Release

Basel, 30 Jan 2012

FDA approves Erivedge (vismodegib) capsule, the first medicine for adults with advanced basal cell carcinoma

Erivedge is a first-in-class Hedgehog Pathway Inhibitor that helps shrink disfiguring or potentially life-threatening lesions in advanced skin cancer

Roche today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation. Erivedge is the first FDA-approved medicine for people with advanced forms of the most common skin cancer. It is a capsule that is taken orally once-a-day.

Basal cell carcinoma is generally considered curable if the cancer is restricted to a small area of the skin. However, in rare cases, lesions can become disfiguring and invade surrounding tissue (locally advanced) or spread to other parts of the body (metastasize). In these cases of advanced BCC, the disease cannot be effectively treated with surgery or radiation. Advanced BCC often results in severe deformity or loss of function of affected organs.

"Today's approval provides a new treatment for people with advanced basal cell carcinoma who, until now, had no approved medicines to help shrink disfiguring or potentially life-threatening lesions," said Hal Barron, M.D., Chief Medical Officer and Head, Global Product Development. "We are pleased that in the last six months we have been able to provide two new medicines for different types of advanced skin cancer to people who previously had few or no treatment options."

Erivedge will be available in the United States within one to two weeks of approval and will be distributed through specialty pharmacies. Roche has also submitted a marketing authorisation application (MAA) for Erivedge in the European Union (EU). In order to provide people with advanced BCC who live outside of the United States access to Erivedge while Roche pursues marketing authorisation world-wide, the company is conducting a phase II safety study in the EU and other countries that is enrolling patients with advanced BCC. For more information, please access http://www.rochetrials.com.

Erivedge efficacy in advanced basal cell carcinoma

The FDA approval of Erivedge is based on results from ERIVANCE BCC (SHH4476g), a pivotal international, single-arm, multicenter, two-cohort, open-label, phase II study that enrolled 104 patients with advanced BCC, including locally advanced BCC (71) and metastatic BCC (33).

The study showed Erivedge shrank lesions (objective response rate, or ORR) in 43 percent (27/63) of patients with locally advanced BCC and 30 percent of patients (10/33) with metastatic BCC, as assessed by independent review, the primary endpoint of the study. The median duration of response was 7.6 months.

Patients with locally advanced BCC had lesions that recurred after surgery, were not candidates for surgery (inoperable, or for whom surgery would result in substantial deformity), recurred after radiotherapy or were not candidates for radiotherapy (radiotherapy was contraindicated or inappropriate). Study participants received 150mg of Erivedge orally, once daily until disease progression or unacceptable toxicity.

Safety information for Erivedge

The most common side effects of Erivedge are muscle spasms, hair loss, change in how things taste or loss of taste, weight loss, tiredness, nausea, diarrhoea, decreased appetite, constipation, vomitting and joint aches. Other side effects may include missed monthly periods in females who can become pregnant, low levels of sodium in the blood, low potassium levels, and a higher than normal blood level of urea or other nitrogen containing compounds in the blood. Patients should tell their healthcare provider if they have any side effect that bothers them or that does not go away.

Please see the full prescribing information for Erivedge, including the Boxed WARNING and Medication Guide at http://www.Erivedge.com.

About basal cell carcinoma and the Hedgehog pathway

BCC is the most common type of skin cancer in Europe1, Australia1,2 and the United States3. In advanced BCC, if the disease is left untreated or recurs in the same location after surgery or radiotherapy, it may advance further into surrounding areas such as sensory organs (ears, nose and eyes), bone, or other tissues. Depending on the location of the lesion, some cases of advanced BCC can be disfiguring, and treatment with surgery or radiation can lead to the loss of sensory organs and their functions such as eyesight or hearing.

The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. Abnormal Hedgehog signaling is implicated in more than 90 percent of BCC cases.

About Erivedge (vismodegib)

Erivedge is an oral medicine designed to selectively inhibit abnormal signaling in the Hedgehog pathway, which is an underlying molecular driver of BCC. Roche and Genentech are also evaluating Erivedge in a Phase II trial in people with operable forms of BCC.

Roche is developing Erivedge under a collaboration agreement with Curis, Inc. Erivedge was discovered by Genentech and jointly validated by Genentech and Curis through a series of preclinical studies. Through this collaboration, Genentech (United States), Roche (ex-United States excluding Japan and Korea) and Chugai Pharmaceuticals (Japan and Korea) are responsible for the clinical development and commercialisation of Erivedge. Curis is eligible to receive cash payments upon the successful achievement of specified clinical development and regulatory approval milestones, as well as royalties upon commercialisation of Erivedge.

For more information about Erivedge, go to http://www.Erivedge.com

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80'000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References

1. N.R.Telfer, G.B.Colver and C.A.Morton. Guidelines for the management of basal cell carcinoma. The British Journal of Dermatology. 2008;158(7):35-48

2. Gilbody JS, et al. What causes basal cell carcinoma to be the commonest cancer? Aust J Public Health.1994; 18(2):218-21

3. Von Hoff et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl J Med. 2009;361:1164-1172

 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org